Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy that usually follows a very aggressive course with a poor prognosis [[1]]. The identification of the same mutation in I ASXL1 i in both tumor and peripheral blood suggests a clonal relationship between the patient's underlying myeloproliferative neoplasm (MPN) and BPDCN. Tagraxofusp, a CD123-directed fusion toxin consisting of human interleukin-3 fused to truncated diphtheria toxin was the first targeted agent for BPDCN and was approved by the United States Food and Drug Administration (FDA) in 2018 [[8]]. [Extracted from the article]